AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12012079
Drug: Bicarbonate supplement
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate supplement
Trial: 10078718
Drug: Oxcarbazepine 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine 1,200 mg twice daily
Trial: 2154855
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus etoposide (cisplatin 120 mg/m2, etoposide 100 mg/m2, days 1 to 3)
Trial: 389813
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg sulphamethoxazole + 160 mg trimethoprim (SMZ + TMP)
Trial: 28855224
Drug: n‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 fatty acid preparation (1.7 g DHA and 0.6 g EPA daily for 6 months)
Trial: 11306214
Drug: Methadone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone treatment interventions
Trial: 7957502
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with DDAVP
Trial: 7957502
Drug: Endonasal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endonasal treatment with DDAVP
Trial: 3661642
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nadolol twice daily
Trial: 3661642
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of nadolol twice daily
Trial: 31490858
Drug: Chemotherapy-periodized exercise
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-periodized exercise prescription
Trial: 31490858
Drug: Standard linear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard linear exercise prescription
Trial: 8638788
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 50 micrograms
Trial: 8638788
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 100 micrograms
Trial: 8638788
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 50 micrograms morphine + 50 micrograms neostigmine
Trial: 1538160
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg ciprofloxacin with loperamide
Trial: 1538160
Drug: 3-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day course of 500 mg ciprofloxacin twice daily with loperamide
Trial: 1538160
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg ciprofloxacin with placebo
Trial: 23018219
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or gonadotropin-releasing hormone agonist
Trial: 17205530
Drug: Non-aspirin NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin NSAIDs (prescription for at least 1 year)
Trial: 7486110
Drug: 3% modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% modified fluid gelatin (GEL)
Trial: 10068848
Drug: Aprindine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprindine (60 mg daily)
Trial: 1903497
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg b.i.d. (increased to 40 mg per day after 8 weeks)
Trial: 1903497
Drug: Cholestyramine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 8 g b.i.d. (added after 16 weeks)
Trial: 1903497
Drug: Gemfibrocil 900
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrocil 900 mg (two thirds of cholestyramine group switched)
Trial: 7342466
Drug: Allyloestrenol (Gestanon)
RxNorm normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allyloestrenol (Gestanon) 10 mg daily until the 8th week, then 15 to 20 mg daily until the 12th week, then tapered off
Trial: 7342466
Drug: Allyloestrenol (Gestanon)
RxNorm normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allyloestrenol (Gestanon) administered immediately after ovulation
Trial: 7342466
Drug: Allyloestrenol (Gestanon)
RxNorm normalized name: allylestrenol
DrugBank: Allylestrenol (DB01431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allyloestrenol (Gestanon) administered after the first missed period
Trial: 19576120
Drug: Nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (120 mg, 3/d)
Trial: 19576120
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg, 3/d)
Trial: 17895886
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5‐fluorouracil (5‐FU) and leucovorin (LV)
Trial: 17895886
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5‐FU and LV
Trial: 11588893
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E intake from supplements
Trial: 11164130
Drug: Age, income,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, income, hormone use, and geographic location
Trial: 9581724
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg twice daily) for 6 months
Trial: 8043664
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) insulin administration
Trial: 48727
Drug: Dexamethasone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (16 mg. per 24 hours for 6 days)
Trial: 23759410
Drug: Website, monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Website, monthly group sessions, and follow-up calls (WG)
Trial: 21486975
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing schedule (0, 2, and 6 months)
Trial: 21486975
Drug: Alternative dosing
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative dosing schedule (0, 3, and 9 months)
Trial: 21486975
Drug: Alternative dosing
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative dosing schedule (0, 6, and 12 months)
Trial: 21486975
Drug: Alternative dosing
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative dosing schedule (0, 12, and 24 months)
Trial: 10955199
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel microsphere, 0.1%
Trial: 23022285
Drug: 6-month pioglitazone
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month pioglitazone treatment
Trial: 10897370
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg)
Trial: 9413087
Drug: Purified chick
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified chick embryo cell rabies vaccine
Trial: 9413087
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell rabies vaccine and human rabies immune globulin
Trial: 9413087
Drug: Chick embryo
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chick embryo vaccine without immune globulin
Trial: 8405014
Drug: 0.150 mg
RxNorm normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.150 mg desogestrel + 0.500 mg 17 beta‐oestradiol cyclo‐octyl acetate
Trial: 8405014
Drug: 0.150 mg
RxNorm normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.150 mg desogestrel + 1.0 mg 17 beta‐oestradiol decanoate
Trial: 2939221
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous ketanserin (0.15 mg/kg)
Trial: 2939221
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral ketanserin (40 mg)
Trial: 2939221
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral ketanserin (40 mg once-daily)
Trial: 29940055
Drug: Single-shot adductor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot adductor canal block (SS-ACB) with 20 mL of 0.5% ropivacaine preoperatively and saline boluses at 12 and 24 hours postoperatively
Trial: 29940055
Drug: Continuous adductor
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous adductor canal block (C-ACB) with 20 mL of 0.5% ropivacaine preoperatively and at 12 and 24 hours postoperatively
Trial: 19758373
Drug: Anti-helminthic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-helminthic therapy
Trial: 9471022
Drug: IFN‐alpha at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha at a dosage of 2‐4 mega units/square metre of body surface area thrice weekly for 6‐12 months
Trial: 9471022
Drug: Higher dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosage and longer treatment duration of IFN‐alpha for patients infected with HCV genotype 1b
Trial: 7525125
Drug: Casodex 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 150 mg daily
Trial: 31769377
Drug: Trial-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial-based cognitive therapy (TBCT)
Trial: 31793418
Drug: Topical Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cannabidiol Oil (250 mg CBD/3 fl. oz)
Trial: 26524798
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (1 mg s.c. injection three days after embryo transfer)
Trial: 21323540
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (0.625 mg in 0.025 ml of solution)
Trial: 17997442
Drug: Parenteral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral estrogen (polyestradiol phosphate)
Trial: 27618916
Drug: Zhengtian Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhengtian Capsule
Trial: 23059435
Drug: Acupuncture (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (30 min twice a week for 5 weeks)
Trial: 8787366
Drug: Artemether (intramuscular,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (intramuscular, given for 5 days)
Trial: 8787366
Drug: Mefloquine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (single oral dose, 25 mg/kg/body-weight)
Trial: 6391154
Drug: 80-g vegetable-protein-supplemented
RxNorm normalized name: VEGETABLE CARBON
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80-g vegetable-protein-supplemented diet (30 g animal and 50 g vegetable, diet B)
Trial: 6391154
Drug: 40-g protein
RxNorm normalized name: soy protein isolate 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-g protein diet (30 g animal and 10 g vegetable, diet A)
Trial: 30318624
Drug: TAC-QD (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-QD (once-daily tacrolimus)
Trial: 30318624
Drug: TAC-BID (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC-BID (twice-daily tacrolimus)
Trial: 26459175
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic therapy (PEXG) without metformin
Trial: 21876066
Drug: Adjunctive levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adjunctive levetiracetam (20-100 mg/kg/d, mean 50.2 mg/kg/d)
Trial: 18314112
Drug: Early CC
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early CC group (100 mg of clomiphene citrate daily starting after medroxyprogesterone acetate for 5 days)
Trial: 18314112
Drug: Late CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late CC group (100 mg of clomiphene citrate daily starting on day 3 of menses for 5 days)
Trial: 18314112
Drug: Late CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late CC group
Trial: 9840608
Drug: PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T vaccine administered at 10 and 14 weeks
Trial: 9840608
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (meningococcal A/C polysaccharide vaccine)
Trial: 9840608
Drug: PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T vaccine (group 2)
Trial: 9840608
Drug: PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T vaccine (both groups)
Trial: 7863249
Drug: Nizatidine 20
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine 20 mg/h
Trial: 1526089
Drug: Nizatidine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (both doses)
Trial: 31765956
Drug: Uninoculated plants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninoculated plants under 200 mg kg-1 Cr stress
Trial: 25487082
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa 2.0 mg/kg administered every other week
Trial: 25559914
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose exercise (150 min/week)
Trial: 25559914
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose exercise (300 min/week)
Trial: 21619917
Drug: Ethanolic extract
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanolic extract of Tulsi leaves (300 mg capsules)
Trial: 14626181
Drug: Composite Salvia
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Salvia Injection (CSI) plus Western Medicine (WM)
Trial: 12080674
Drug: Western Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western Medicine (WM)
Trial: 11099285
Drug: Non-directive counselling
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-directive counselling and Cognitive-behaviour therapy
Trial: 29727013
Drug: Everolimus, target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus, target Cmin range of 5-7 ng/mL initially and 5-15 ng/mL for inadequate response.
Trial: 21920335
Drug: Atorvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin monotherapy or atorvastatin-based combination therapies
Trial: 18312050
Drug: Methylphenidate transdermal
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate transdermal system patch (10-30 mg, 9-hour wear time)
Trial: 18312050
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate capsule (18-54 mg)
Trial: 25335329
Drug: Shugan Jiangu
RxNorm normalized name: Jiang Huang (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shugan Jiangu Recipe (SJR), 6 g twice daily for 6 months
Trial: 10406689
Drug: Heparin-coated stents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated stents
Trial: 11996329
Drug: Capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation of R115777 (300 or 400 mg)
Trial: 9702468
Drug: Miglitol (BAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (BAY m 1099), 100 mg tds
Trial: 2685532
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g plain aspirin (swallowed)
Trial: 800971
Drug: 0.25% desoxymethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% desoxymethasone ointment
Trial: 6370438
Drug: 0.05% fluocinonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% fluocinonide ointment
Trial: 27297851
Drug: Levosimendan (0.05-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.05-0.2 μg/[kg min])
Trial: 24053564
Drug: placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (two tablets twice daily)
Trial: 12412834
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion (300 mg/day)
Trial: 12439626
Drug: Nefazodone (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (450 mg/day)
Trial: 12412834
Drug: Oral delta9-THC
RxNorm normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral delta9-THC (10, 20, 30 mg PO)
Trial: 2403818
Drug: 7‐3‐7 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3‐7 regimen (same drugs intensified with etoposide 75 mg/m2/d IV days 1-7)
Trial: 30904553
Drug: Simultaneous implant
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous implant and CTG placement (test group)
Trial: 16424413
Drug: Cilomilast, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast, 15 mg bid
Trial: 28877913
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/d
Trial: 11355925
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy including high-dose Ara-C
Trial: 9397386
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 micrograms/day and NETA (170 micrograms/day) given continuously
Trial: 9397386
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 micrograms/day and NETA (350 micrograms/day) given continuously
Trial: 9397386
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 micrograms/day and NETA given sequentially (last 14 days of each treatment cycle)
Trial: 2492744
Drug: Carnitine-free total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine-free total parenteral nutrition (TPN)
Trial: 3148789
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (12 mg/kg.day)
Trial: 23452524
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative analgesic methods (applied to all patients).
Trial: 17885551
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor ramipril
Trial: 8908384
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ACE inhibitor and Vitamin E
Trial: 27338216
Drug: Emergency Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency Medicine
Trial: 7996346
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered methylprednisolone, 30 mg/kg per day for 7 days (n = 19)
Trial: 7996346
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered methylprednisolone, 50 mg/kg per day for 7 days (n = 19)
Trial: 3281399
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg, suppositories, 3 times a day for 3 days)
Trial: 1555873
Drug: Heparin-coated extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated extracorporeal circuit (Carmeda)
Trial: 1555873
Drug: Non-heparin-coated extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin-coated extracorporeal circuit (Scimed)
Trial: 638969
Drug: Intralesional BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional BCG therapy